Skip to main content

Table 1 Baseline characteristics of the 53 patients

From: Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study

  Mean ± SD
Control group (n = 23) Diabetic group (n = 30)
Sex (male/female) 5/18 17/13
Age (year) 43.5 ± 16.5 68.5 ± 7.4
Height (cm) 165.2 ± 11.3 160.7 ± 8.4
Weight (kg) 60.9 ± 15.0 62.6 ± 13.4
BMI (kg/m2) 22.0 ± 3.3 24.1 ± 3.9
SBP (mmHg) 116.2 ± 11.5 134.8 ± 17.0
DBP (mmHg) 69.1 ± 9.1 73.5 ± 9.0
Duration of diabetes (year)   14.7 ± 11.5
HbA1c (%)   6.7 ± 0.6
Creatinine (mg/dl)   0.87 ± 0.26
eGFR (mL/min/1.73 m2)   63.5 ± 14.8
Neuropathy, n (%)   8 (26.7)
Retinopathy, n (%)   3 (10.0)
Nephropathy, n (%)   6 (20.0)
Anti-diabetes treatment   
 Diet only, n (%)   1 (3.0)
 SU, n (%)   0 (0)
 Glinide, n (%)   2 (6.7)
 DPP-4 inhibitor, n (%)   21 (70.0)
 Biguanide, n (%)   15 (50.0)
 Thiazolidine, n (%)   5 (16.7)
 SGLT-2 inhibitor, n (%)   7 (23.3)
 α-glucose inhibitor, n (%)   7 (23.3)
 GLP-1 receptor, n (%)   3 (10.0)
 Insulin, n (%)   6 (20.0)
  1. Sex, by χ2 test. Age, by Welch test. BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, eGFR estimated glomerular filtration rate, SU sulfonylureas, DPP-4 inhibitor dipeptidyl peptidase-4 inhibitor, SGLT-2 inhibitor sodium-glucose transporter-2 inhibitor, GLP-1 receptor Glucagon-like peptide-1 receptor